JENA, Germany — August 21, 2025 — Leads & Copy — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company, announced its participation in two investor conferences in September 2025. The Cantor Global Healthcare Conference 2025 will be held September 3-5 in New York, NY, with a fireside chat on September 4th at 9:10 AM ET. InflaRx will also conduct one-on-one investor meetings on September 4th. A link to view the fireside chat live stream and its replay is available here.
The H.C. Wainwright 27th Annual Global Investment Conference will be held September 8-10 in New York, NY, featuring a presentation on September 9th at 3:30 PM ET. InflaRx will also conduct one-on-one investor meetings on September 9th. A link to register for the presentation live stream and its replay is available here.
InflaRx (Nasdaq: IFRX) focuses on anti-inflammatory therapeutics, applying its anti-C5a and anti-C5a receptor technologies to develop inhibitors of the complement activation factor C5a and its receptor. Its lead product, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody. The company is also developing INF904, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor. InflaRx was founded in 2007 and has offices in Jena and Munich, Germany, and Ann Arbor, MI, USA.
Jan Medina, CFA, Vice President, Head of Investor Relations, IR@inflarx.de
Katja Arnold, Laurie Doyle, Dr. Regina Lutz, inflarx@mc-services.eu, Europe: +49 89-210 2280, U.S.: +1-339-832-0752
Source: InflaRx
